Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

PURPOSE: Non-small-cell lung cancer (NSCLC) has a large worldwide prevalence with a high mortality rate. Chemotherapy has offered modest improvements in survival over the past two decades. Immune checkpoint modulation with programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibition has...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Front Oncol
Huvudupphovsmän: Iafolla, Marco A. J., Juergens, Rosalyn A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2017
Ämnen:
Oncology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5382272/
https://ncbi.nlm.nih.gov/pubmed/28428947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00067
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk